Zura Bio Limited ZURA
Zura Bio Limited (Nasdaq: ZURA) is a dermatology drug developer. Its lead program, tibulizumab (ZB-106), is in Phase 2 for hidradenitis suppurativa. Its next catalyst on record is tibulizumab: NEXUS-PMR Phase 2 study in polymyalgia rheumatica remains on track to initiate by year-end 2026. (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: tibulizumab — NEXUS-PMR Phase 2 study in polymyalgia rheumatica remains on track to initiate by year-end 2026. (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| tibulizumab (ZB-106) | hidradenitis suppurativa | antibody | Phase 2 |
| tibulizumab (ZB-106) | diffuse cutaneous systemic sclerosis | antibody | Phase 2 |
| tibulizumab (ZB-106) | polymyalgia rheumatica | antibody | Phase 2 |
| torudokimab (ZB-880) | inflammatory and immune-mediated diseases | antibody | Phase 1 |
| crebankitug (ZB-168) | under evaluation | antibody | Phase 1 |
Recent results and decisions
- Oct 27, 2026accepted NEXUS-PMR Phase 2 study cleared by FDA to proceed under an Investigational New Drug application.
The Phase 2 clinical study evaluating tibulizumab in adults with polymyalgia rheumatica, an inflammatory disease in which most patients remain dependent on long-term glucocorticoids, has been cleared by the U.S. Food and Drug Administration (FDA) to proceed under an Investigational New Drug applicat
Filing - Oct 27, 2026n/a NEXUS-PMR Phase 2 study in polymyalgia rheumatica has been cleared by FDA and remains on track to initiate by year-end 2026.
NEXUS-PMR (PMR): The Phase 2 clinical study evaluating tibulizumab in adults with polymyalgia rheumatica has been cleared by the U.S. Food and Drug Administration (FDA) to proceed under an Investigational New Drug application and remains on track to initiate by year-end 2026.
Filing - Oct 27, 2026submitted Zura's IND for tibulizumab in polymyalgia rheumatica has been cleared by the FDA to proceed.
The Phase 2 clinical study evaluating tibulizumab in adults with polymyalgia rheumatica, an inflammatory disease in which most patients remain dependent on long-term glucocorticoids, has been cleared by the U.S. Food and Drug Administration (FDA) to proceed under an Investigational New Drug applicat
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.